This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Administered through a unique helmet in an outpatient procedure that doesn’t require hospitalization or anesthesia, and entailing no memory loss or systemic side effects, BrainsWay therapy can help regain stability and routine within just a few weeks.
The treatment is CE cleared for treating numerous conditions including Autism, Alzheimer’s, Bipolar Disorder, Chronic Pain, Major Depressive Disorder, Parkinson Disease, Schizophrenia (negative symptoms), Smoking Cessation, Post-Traumatic Stress Disorder, Multiple Sclerosis, Obsessive Compulsive Disorder and Stroke Rehabilitation.
A widely tested treatment, BrainsWay therapy has been utilized in over 60 clinical trials worldwide. It is based on patents registered by the U.S. National Institutes of Health (NIH) and the company.